PSMD7

Across TCGA pan-cancer cohorts, PSMD7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSMD7 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSMD7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PSMD7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, COAD, and UCEC are the cancer types where PSMD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.993	0.412	.035	10	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
UCEC	OS	Median	II,III,IV	1.000	0.638	.014	4	view →
CCRCC	OS	Quartile	III,IV	0.563	0.866	.047	1	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSMD7–LUAD (DFS)

Open the LUAD breakdown →